Cargando…
Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece
OBJECTIVE: The objectives of this study were to elicit self-reported health status, quantify osteoporosis-related burden, and understand preferences for treatment attributes among postmenopausal women with severe osteoporosis in Greece. METHODS: Postmenopausal women with self-reported severe osteopo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840367/ https://www.ncbi.nlm.nih.gov/pubmed/36647442 http://dx.doi.org/10.2147/PPA.S385351 |
_version_ | 1784869626926071808 |
---|---|
author | Souliotis, Kyriakos Golna, Christina Poimenidou, Christina Drakopoulou, Tatiana Tsekoura, Memi Willems, Damon Kountouris, Vasileios Makras, Polyzois |
author_facet | Souliotis, Kyriakos Golna, Christina Poimenidou, Christina Drakopoulou, Tatiana Tsekoura, Memi Willems, Damon Kountouris, Vasileios Makras, Polyzois |
author_sort | Souliotis, Kyriakos |
collection | PubMed |
description | OBJECTIVE: The objectives of this study were to elicit self-reported health status, quantify osteoporosis-related burden, and understand preferences for treatment attributes among postmenopausal women with severe osteoporosis in Greece. METHODS: Postmenopausal women with self-reported severe osteoporosis, defined as having suffered at least one osteoporotic fracture and reporting a T-score of ≤−2.5, were asked to evaluate their health status, osteoporosis management, and disease-related physical, emotional, and financial burden. Participants were also asked to rate a series of treatment attributes and state their preference for unlabeled anabolic treatments, based on scenarios describing key treatment characteristics. RESULTS: Approximately one third (31%) of the 186 participants who responded to the survey in full had been living with severe osteoporosis for more than 10 years. Three quarters of participants (72%) considered their overall quality of life (QoL) to be worse than it had been 10 years prior, and the vast majority (89%) attributed this deterioration to osteoporosis. Direct, out of pocket, disease-related costs of at least €100 per month were reported by 86% of participants. Patients attached the greatest value to a treatment that would decrease probability of future fractures, followed by increase in bone density, safety, and mode and frequency of administration. When asked to select their preferred treatment scenario between two anabolic treatments, 70% of participants opted for the scenario that shared treatment characteristics with romosozumab over a scenario that shared treatment characteristics with teriparatide. CONCLUSION: Our study revealed that osteoporosis placed a considerable burden on QoL for postmenopausal women with severe osteoporosis in Greece. Patients reported valuing treatment efficacy, measured through reduction in future fractures and increase in bone density, and safety, as key treatment attributes. |
format | Online Article Text |
id | pubmed-9840367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-98403672023-01-15 Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece Souliotis, Kyriakos Golna, Christina Poimenidou, Christina Drakopoulou, Tatiana Tsekoura, Memi Willems, Damon Kountouris, Vasileios Makras, Polyzois Patient Prefer Adherence Original Research OBJECTIVE: The objectives of this study were to elicit self-reported health status, quantify osteoporosis-related burden, and understand preferences for treatment attributes among postmenopausal women with severe osteoporosis in Greece. METHODS: Postmenopausal women with self-reported severe osteoporosis, defined as having suffered at least one osteoporotic fracture and reporting a T-score of ≤−2.5, were asked to evaluate their health status, osteoporosis management, and disease-related physical, emotional, and financial burden. Participants were also asked to rate a series of treatment attributes and state their preference for unlabeled anabolic treatments, based on scenarios describing key treatment characteristics. RESULTS: Approximately one third (31%) of the 186 participants who responded to the survey in full had been living with severe osteoporosis for more than 10 years. Three quarters of participants (72%) considered their overall quality of life (QoL) to be worse than it had been 10 years prior, and the vast majority (89%) attributed this deterioration to osteoporosis. Direct, out of pocket, disease-related costs of at least €100 per month were reported by 86% of participants. Patients attached the greatest value to a treatment that would decrease probability of future fractures, followed by increase in bone density, safety, and mode and frequency of administration. When asked to select their preferred treatment scenario between two anabolic treatments, 70% of participants opted for the scenario that shared treatment characteristics with romosozumab over a scenario that shared treatment characteristics with teriparatide. CONCLUSION: Our study revealed that osteoporosis placed a considerable burden on QoL for postmenopausal women with severe osteoporosis in Greece. Patients reported valuing treatment efficacy, measured through reduction in future fractures and increase in bone density, and safety, as key treatment attributes. Dove 2023-01-10 /pmc/articles/PMC9840367/ /pubmed/36647442 http://dx.doi.org/10.2147/PPA.S385351 Text en © 2023 Souliotis et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Souliotis, Kyriakos Golna, Christina Poimenidou, Christina Drakopoulou, Tatiana Tsekoura, Memi Willems, Damon Kountouris, Vasileios Makras, Polyzois Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece |
title | Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece |
title_full | Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece |
title_fullStr | Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece |
title_full_unstemmed | Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece |
title_short | Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece |
title_sort | disease burden and treatment preferences amongst postmenopausal women with severe osteoporosis in greece |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840367/ https://www.ncbi.nlm.nih.gov/pubmed/36647442 http://dx.doi.org/10.2147/PPA.S385351 |
work_keys_str_mv | AT souliotiskyriakos diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece AT golnachristina diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece AT poimenidouchristina diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece AT drakopouloutatiana diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece AT tsekouramemi diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece AT willemsdamon diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece AT kountourisvasileios diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece AT makraspolyzois diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece |